on major coronary events in hypercholesterolaemic patients (JELIS): a Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded. Significant reduction in residual risk in patients treated with statins. Results from the JELIS (Japan EPA Lipid Intervention Study) trial. EPA may have beneficial.
|Published (Last):||9 October 2015|
|PDF File Size:||3.22 Mb|
|ePub File Size:||1.67 Mb|
|Price:||Free* [*Free Regsitration Required]|
The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including jeli angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. These observations suggest that at least some of the impact of VASCEPA on the reduction in ischemic events may be explained by metabolic effects other than triglyceride lowering.
Epidemiological and clinical evidence suggests that an increased intake of long-chain n-3 fatty acids protects against mortality from coronary artery disease. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash. Further detailed data assessment by Amarin and regulatory authorities will continue and take several months to complete and record The final evaluation of the totality of the efficacy and safety data from REDUCE-IT may include some or all of the following, as well as other considerations: The omega-3 fatty acid mixtures studied in such other outcomes trials were primarily comprised of EPA and docosahexaenoic acid DHA typically, approximately mg total per 1 gram capsule and also typically included a number of other omega-3 and omega-6 acids, as well as other constituents.
VASCEPA® (icosapent ethyl) | REDUCE-IT™ Results Announced
The trial population was This information on inflammatory markers cannot be used in isolation. This offer is not valid for those patients under 18 years of age or patients whose plans do not permit use of a copay card.
P values from Wilcoxon rank sum test. Void where prohibited by law, taxed, or restricted. Mineral oil placebo consideration and analysis. The median age at baseline was 64 years range: Most patients at baseline were taking at least one other cardiovascular medication including anti-platelet agents GISSI-P did not suggest an effect on the incidence of nonfatal cardiovascular events and the effects of omega-3 fatty acids on lipids, including serum TGs, were negligible.
By working together and supporting these efforts, inside and outside of the company, Amarin can empower, share and learn as it strides toward the unified goal of excellence—and beyond. The changes in the major lipoprotein lipid parameters for the groups receiving VASCEPA plus statin or placebo plus statin are shown in the table.
Not for use by residents of VT, nor medical professionals licensed in VT. No head-to-head cardiovascular outcomes study of EPA vs a mixture of omega-3 acids has been conducted. We aimed to test the hypothesis that long-term use of eicosapentaenoic acid EPA is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish.
Amarin, through its dedicated team of professionals, constantly seeks to improve patient care through its actions and products while also striving to continuously improve along the way.
Nat Clin Pract Cardiovasc Med. Prespecified hierarchical testing of other secondary endpoints revealed significant reductions in the following:. The study was registered at ClinicalTrials. Am J Cardiovasc Drugs.
Yes No By clicking yes, you are certifying you are also a US resident.
The median change in LDL-C was 3. On stable background lipid-lowering therapy, the median [Q1, Q3] fasting TG was At mean follow-up of 4. Estimated hazard ratios of clinical endpoints stratified by prevention stratum; Saito je,is al, Figure 3: The primary, secondary, and tertiary adjudicated endpoint analyses were validated by the data monitoring committee independent statistician.
Watch the national commercial. This focus includes a commitment to research and education in cardiovascular health. Stydy rate of treatment-emergent serious adverse events for bleeding was 2.
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: The Kaplan-Meier estimates of the cumulative incidence of the kelis and key secondary composite endpoints over time are shown in Figure 1 and Figure 2 below.
Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Curves were visually truncated at 5. Patients enrolled were treated with statin therapy at baseline with most While the DMC noted variation in LDL-C measurements in both arms and that a small physiological effect of mineral oil might be possible, the DMC concluded that it was not possible to determine if the LDL-C increase in the placebo arm was a natural increase over time or due to the mineral jells, they found no apparent effect on outcomes and found that this small change was unlikely to explain the observed benefit of VASCEPA over placebo.
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia [published online ahead of print November 10, ].
Patients were randomly assigned 1: Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events. Analysis was by intention-to-treat. In patients with severe hypertriglyceridemia, the effect of VASCEPA on cardiovascular mortality or morbidity or on the risk of pancreatitis has not been determined. P values for Lp-PLA 2a secondary endpoint, were adjusted jeelis multiple comparisons; all other endpoints are exploratory.